Advertisement
UK markets open in 6 hours 19 minutes

  • NIKKEI 225

    37,954.60
    -505.48 (-1.31%)
     

  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     

  • CRUDE OIL

    82.74
    -0.07 (-0.08%)
     

  • GOLD FUTURES

    2,330.30
    -8.10 (-0.35%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • Bitcoin GBP

    51,801.42
    -1,689.30 (-3.16%)
     

  • CMC Crypto 200

    1,391.47
    -32.63 (-2.29%)
     

  • NASDAQ Composite

    15,712.75
    +16.11 (+0.10%)
     

  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

Why Athira Pharma Stock Imploded Today

Alex Carchidi, The Motley Fool
·2-min read

Athira Pharma's (NASDAQ: ATHA) stock crumbled by more than 69.5% as of 10:04 a.m. ET Wednesday after the company reported that results from a phase 2 clinical trial for its drug treating mild to moderate Alzheimer's disease didn't reach statistical significance. The phase 2 failure bodes poorly for Athira's future, as it still has an ongoing phase 3 trial for fosgonimeton in Alzheimer's disease that's due to finish enrollment by the end of the third quarter.

Continue reading